Close

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

New Endometrial Cancer Therapy Phase-II Trial Shows Promise

The most recent trial of a new antibody drug...

Duality Looks Out For Hong Kong IPO To Finance ADC Trials

Duality Biotherapeutics from China has gone ahead and filed...

PhotonPharma Secures $2.5 Million in Seed Funding to Advance Clinical Trial for Ovarian Cancer Treatment

PhotonPharma, a cutting-edge biopharmaceutical company based in Fort Collins,...

Thermo Fisher Scientific, the world leader in serving science announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan.

This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies. As a leading service provider to the cell and gene therapy community, Fisher BioServices is uniquely positioned with the experience, resources, and global expertise to support its customers on their path towards commercialization.

The facility in Tokyo was expanded to include cryogenic storage and logistics by utilizing a combination of proven components and validated procedures developed with years of experience in the cell and gene therapy business. The new modules within this facility allow Fisher BioServices to configure and replicate each site to meet the specific requirements of individual clinical trials with minimal variation, regardless of volume or geographic location. The facility is also supported by a global comprehensive and integrated Quality System based on regulatory requirements, industry best practices and trained personnel.

“Japan is an increasingly important market for cell and gene therapy companies conducting clinical trials,” said Dennis Barger, Fisher BioServices vice president and general manager. “The addition of cryogenic services to this facility in Japan, combined with our existing capabilities in Europe and the US, enables us to seamlessly support our customers’ global trials as they develop and commercialize their therapies.”

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com

Contact:

Thermo Fisher Scientific
Marcia K. Goff, +1-508-902-7041
marcia.goff@thermofisher.com

 

Latest stories